| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 122 | 2024 | 316 | 31.720 |
Why?
|
| Biomarkers | 65 | 2024 | 1773 | 5.090 |
Why?
|
| Cardiac Surgical Procedures | 31 | 2023 | 480 | 4.090 |
Why?
|
| Sepsis | 10 | 2024 | 328 | 3.790 |
Why?
|
| Renal Replacement Therapy | 15 | 2024 | 35 | 3.710 |
Why?
|
| Creatinine | 32 | 2023 | 294 | 3.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 12 | 2023 | 24 | 3.040 |
Why?
|
| Critical Illness | 17 | 2024 | 311 | 2.840 |
Why?
|
| Artificial Intelligence | 8 | 2023 | 329 | 2.630 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 12 | 2023 | 22 | 2.250 |
Why?
|
| Renal Insufficiency, Chronic | 11 | 2023 | 221 | 2.220 |
Why?
|
| Kidney | 18 | 2023 | 1148 | 2.210 |
Why?
|
| Renal Dialysis | 14 | 2024 | 337 | 2.080 |
Why?
|
| Nephrology | 6 | 2023 | 42 | 1.890 |
Why?
|
| Furosemide | 7 | 2023 | 34 | 1.860 |
Why?
|
| Cystatin C | 12 | 2018 | 27 | 1.770 |
Why?
|
| Lipocalins | 13 | 2015 | 35 | 1.650 |
Why?
|
| Humans | 142 | 2024 | 89785 | 1.610 |
Why?
|
| Acute-Phase Proteins | 13 | 2015 | 37 | 1.540 |
Why?
|
| Aftercare | 2 | 2022 | 88 | 1.440 |
Why?
|
| Prospective Studies | 42 | 2023 | 4320 | 1.280 |
Why?
|
| Intensive Care Units | 9 | 2024 | 397 | 1.250 |
Why?
|
| Proto-Oncogene Proteins | 13 | 2015 | 665 | 1.250 |
Why?
|
| Postoperative Complications | 15 | 2021 | 2299 | 1.190 |
Why?
|
| Delphi Technique | 3 | 2024 | 101 | 1.170 |
Why?
|
| Machine Learning | 3 | 2023 | 268 | 1.150 |
Why?
|
| Interleukin-18 | 9 | 2016 | 26 | 1.130 |
Why?
|
| Respiration, Artificial | 7 | 2022 | 358 | 1.120 |
Why?
|
| Risk Assessment | 14 | 2023 | 2315 | 1.100 |
Why?
|
| Chemokines, CC | 3 | 2024 | 36 | 1.090 |
Why?
|
| Glomerular Filtration Rate | 12 | 2020 | 277 | 1.070 |
Why?
|
| Urinalysis | 4 | 2021 | 31 | 1.060 |
Why?
|
| Lipocalin-2 | 17 | 2023 | 37 | 1.030 |
Why?
|
| Precision Medicine | 6 | 2024 | 412 | 1.000 |
Why?
|
| Kidney Function Tests | 8 | 2017 | 115 | 0.980 |
Why?
|
| Risk Factors | 23 | 2022 | 5539 | 0.940 |
Why?
|
| Early Diagnosis | 10 | 2023 | 125 | 0.910 |
Why?
|
| Diuretics | 5 | 2018 | 75 | 0.900 |
Why?
|
| Patient Discharge | 2 | 2024 | 324 | 0.900 |
Why?
|
| Oliguria | 2 | 2024 | 6 | 0.870 |
Why?
|
| Hospitalization | 7 | 2023 | 883 | 0.820 |
Why?
|
| Kidney Diseases | 4 | 2017 | 320 | 0.810 |
Why?
|
| Middle Aged | 46 | 2024 | 26080 | 0.810 |
Why?
|
| Aged | 44 | 2024 | 19212 | 0.810 |
Why?
|
| Male | 60 | 2024 | 42582 | 0.790 |
Why?
|
| Biological Assay | 1 | 2022 | 79 | 0.790 |
Why?
|
| Heart Failure | 3 | 2020 | 1196 | 0.770 |
Why?
|
| Severity of Illness Index | 11 | 2024 | 1856 | 0.740 |
Why?
|
| Dialysis Solutions | 1 | 2020 | 7 | 0.740 |
Why?
|
| Female | 59 | 2024 | 46494 | 0.740 |
Why?
|
| Electronic Health Records | 4 | 2024 | 351 | 0.710 |
Why?
|
| Kidney Failure, Chronic | 3 | 2015 | 414 | 0.680 |
Why?
|
| Prognosis | 18 | 2023 | 3785 | 0.660 |
Why?
|
| Mobile Applications | 1 | 2020 | 71 | 0.650 |
Why?
|
| Patient Care | 1 | 2020 | 102 | 0.650 |
Why?
|
| Kidney Tubules | 3 | 2017 | 92 | 0.650 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 54 | 0.640 |
Why?
|
| ROC Curve | 9 | 2024 | 776 | 0.630 |
Why?
|
| Hemofiltration | 1 | 2018 | 9 | 0.630 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2021 | 188 | 0.600 |
Why?
|
| Albuminuria | 6 | 2016 | 48 | 0.600 |
Why?
|
| Adult | 25 | 2024 | 26767 | 0.590 |
Why?
|
| Aged, 80 and over | 21 | 2021 | 6778 | 0.580 |
Why?
|
| Predictive Value of Tests | 13 | 2022 | 1729 | 0.580 |
Why?
|
| Creatine | 1 | 2017 | 25 | 0.570 |
Why?
|
| Area Under Curve | 6 | 2019 | 336 | 0.560 |
Why?
|
| Liver Diseases | 2 | 2015 | 242 | 0.540 |
Why?
|
| Kidney Glomerulus | 1 | 2017 | 122 | 0.530 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 206 | 0.530 |
Why?
|
| Physicians | 1 | 2023 | 691 | 0.520 |
Why?
|
| Delivery of Health Care | 5 | 2023 | 436 | 0.510 |
Why?
|
| Cohort Studies | 18 | 2022 | 2886 | 0.510 |
Why?
|
| Coronary Artery Bypass | 3 | 2019 | 236 | 0.510 |
Why?
|
| Arterial Pressure | 1 | 2015 | 38 | 0.490 |
Why?
|
| Multiple Organ Failure | 3 | 2023 | 53 | 0.490 |
Why?
|
| Acute Lung Injury | 2 | 2009 | 64 | 0.480 |
Why?
|
| Critical Care | 6 | 2023 | 384 | 0.470 |
Why?
|
| Cytokines | 1 | 2018 | 811 | 0.470 |
Why?
|
| Pharmacogenetics | 4 | 2019 | 437 | 0.460 |
Why?
|
| Ventilator-Induced Lung Injury | 2 | 2015 | 31 | 0.460 |
Why?
|
| Retrospective Studies | 11 | 2024 | 9159 | 0.450 |
Why?
|
| Disease Progression | 7 | 2021 | 1466 | 0.450 |
Why?
|
| Patient Care Team | 2 | 2015 | 284 | 0.450 |
Why?
|
| Renal Insufficiency | 2 | 2023 | 98 | 0.430 |
Why?
|
| Time Factors | 12 | 2016 | 5350 | 0.430 |
Why?
|
| Workload | 1 | 2014 | 129 | 0.430 |
Why?
|
| Quality Improvement | 4 | 2023 | 457 | 0.420 |
Why?
|
| Consensus | 6 | 2024 | 365 | 0.420 |
Why?
|
| Anuria | 1 | 2012 | 6 | 0.400 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2012 | 12 | 0.400 |
Why?
|
| Proteinuria | 5 | 2021 | 67 | 0.390 |
Why?
|
| Survivors | 2 | 2024 | 234 | 0.390 |
Why?
|
| Algorithms | 2 | 2018 | 1904 | 0.390 |
Why?
|
| Clinical Trials as Topic | 5 | 2024 | 1134 | 0.370 |
Why?
|
| Oxygen | 1 | 2015 | 745 | 0.350 |
Why?
|
| Models, Biological | 1 | 2016 | 1765 | 0.330 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 715 | 0.330 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 5 | 2016 | 17 | 0.310 |
Why?
|
| Cell Cycle Checkpoints | 3 | 2019 | 66 | 0.300 |
Why?
|
| Incidence | 5 | 2021 | 1598 | 0.300 |
Why?
|
| Membrane Glycoproteins | 4 | 2015 | 431 | 0.290 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 251 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 1052 | 0.290 |
Why?
|
| Antioxidants | 1 | 2008 | 226 | 0.280 |
Why?
|
| Drug Prescriptions | 2 | 2019 | 141 | 0.280 |
Why?
|
| Child | 9 | 2023 | 7233 | 0.270 |
Why?
|
| Motor Activity | 4 | 2002 | 327 | 0.270 |
Why?
|
| Heart-Assist Devices | 1 | 2014 | 763 | 0.270 |
Why?
|
| Receptors, Virus | 4 | 2015 | 75 | 0.260 |
Why?
|
| Sensitivity and Specificity | 5 | 2019 | 2018 | 0.260 |
Why?
|
| Models, Statistical | 2 | 2020 | 575 | 0.260 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 280 | 0.250 |
Why?
|
| Blood Pressure | 1 | 2009 | 902 | 0.250 |
Why?
|
| Quantitative Trait, Heritable | 3 | 2001 | 124 | 0.250 |
Why?
|
| Crosses, Genetic | 4 | 2002 | 171 | 0.240 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 848 | 0.240 |
Why?
|
| United States | 9 | 2024 | 7083 | 0.240 |
Why?
|
| Blood Urea Nitrogen | 2 | 2016 | 34 | 0.240 |
Why?
|
| Ligands | 2 | 2023 | 447 | 0.230 |
Why?
|
| Fluid Therapy | 2 | 2018 | 51 | 0.230 |
Why?
|
| Hypertension | 1 | 2009 | 747 | 0.220 |
Why?
|
| Chromosome Mapping | 3 | 2002 | 1074 | 0.220 |
Why?
|
| Europe | 1 | 2024 | 324 | 0.220 |
Why?
|
| Comorbidity | 2 | 2018 | 952 | 0.210 |
Why?
|
| Pharmacogenomic Testing | 3 | 2019 | 95 | 0.210 |
Why?
|
| Length of Stay | 3 | 2022 | 744 | 0.210 |
Why?
|
| Costs and Cost Analysis | 1 | 2023 | 153 | 0.200 |
Why?
|
| Patients | 1 | 2023 | 102 | 0.200 |
Why?
|
| Noninvasive Ventilation | 1 | 2022 | 24 | 0.200 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 983 | 0.190 |
Why?
|
| Hospital Mortality | 2 | 2022 | 403 | 0.190 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2018 | 27 | 0.190 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2013 | 91 | 0.190 |
Why?
|
| Chemokine CCL2 | 1 | 2021 | 47 | 0.190 |
Why?
|
| Congresses as Topic | 2 | 2019 | 115 | 0.190 |
Why?
|
| Heart Diseases | 2 | 2015 | 299 | 0.190 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 172 | 0.190 |
Why?
|
| Epidermal Growth Factor | 1 | 2021 | 117 | 0.180 |
Why?
|
| Child, Preschool | 7 | 2023 | 3765 | 0.180 |
Why?
|
| Research Design | 1 | 2024 | 591 | 0.180 |
Why?
|
| Water Supply | 1 | 2020 | 61 | 0.180 |
Why?
|
| Glutathione Transferase | 2 | 2010 | 112 | 0.180 |
Why?
|
| Benchmarking | 1 | 2020 | 79 | 0.180 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 3663 | 0.170 |
Why?
|
| Respiratory Insufficiency | 1 | 2022 | 161 | 0.170 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2019 | 12 | 0.170 |
Why?
|
| Diuresis | 1 | 2019 | 26 | 0.170 |
Why?
|
| Galectin 3 | 1 | 2019 | 20 | 0.170 |
Why?
|
| Point-of-Care Systems | 2 | 2019 | 146 | 0.170 |
Why?
|
| Polymorphism, Genetic | 3 | 2009 | 825 | 0.170 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 102 | 0.170 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2019 | 5 | 0.160 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2019 | 67 | 0.160 |
Why?
|
| Preventive Health Services | 1 | 2019 | 39 | 0.160 |
Why?
|
| Recombination, Genetic | 2 | 2001 | 446 | 0.160 |
Why?
|
| Disease Management | 2 | 2019 | 326 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2018 | 8243 | 0.160 |
Why?
|
| Intraoperative Period | 1 | 2018 | 91 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2019 | 34 | 0.160 |
Why?
|
| Urination | 1 | 2018 | 38 | 0.160 |
Why?
|
| Urodynamics | 1 | 2019 | 123 | 0.160 |
Why?
|
| Young Adult | 5 | 2019 | 6386 | 0.160 |
Why?
|
| Postoperative Period | 3 | 2014 | 301 | 0.150 |
Why?
|
| Exercise Test | 2 | 2023 | 166 | 0.150 |
Why?
|
| Community Health Services | 1 | 2019 | 82 | 0.150 |
Why?
|
| Hospitals | 1 | 2020 | 303 | 0.150 |
Why?
|
| Delayed Graft Function | 1 | 2017 | 14 | 0.150 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 854 | 0.150 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2016 | 25 | 0.140 |
Why?
|
| Neoplasms | 3 | 2018 | 3062 | 0.140 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 27 | 0.140 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 744 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 405 | 0.140 |
Why?
|
| Nephrologists | 1 | 2016 | 10 | 0.140 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 149 | 0.140 |
Why?
|
| Patients' Rooms | 1 | 2016 | 14 | 0.140 |
Why?
|
| Renin-Angiotensin System | 1 | 2017 | 81 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2023 | 1175 | 0.130 |
Why?
|
| Cisplatin | 1 | 2018 | 598 | 0.130 |
Why?
|
| Azotemia | 1 | 2015 | 1 | 0.130 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2015 | 4 | 0.130 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2014 | 160 | 0.130 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2015 | 10 | 0.130 |
Why?
|
| Probability | 1 | 2016 | 350 | 0.130 |
Why?
|
| Perioperative Period | 1 | 2015 | 25 | 0.130 |
Why?
|
| Physician's Role | 1 | 2017 | 176 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 563 | 0.120 |
Why?
|
| Uromodulin | 1 | 2015 | 15 | 0.120 |
Why?
|
| Containment of Biohazards | 1 | 2015 | 9 | 0.120 |
Why?
|
| Physician-Patient Relations | 2 | 2019 | 624 | 0.120 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2015 | 12 | 0.120 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2015 | 32 | 0.120 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 1607 | 0.120 |
Why?
|
| Forecasting | 1 | 2015 | 304 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2017 | 502 | 0.110 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 72 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 840 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2015 | 186 | 0.110 |
Why?
|
| Genome, Human | 1 | 2019 | 791 | 0.110 |
Why?
|
| Sodium | 1 | 2015 | 331 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 399 | 0.110 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2013 | 39 | 0.110 |
Why?
|
| Contrast Media | 1 | 2018 | 1084 | 0.110 |
Why?
|
| Erythrocyte Transfusion | 1 | 2014 | 73 | 0.110 |
Why?
|
| Genomics | 1 | 2009 | 776 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2014 | 148 | 0.110 |
Why?
|
| Pregnancy | 1 | 2020 | 3040 | 0.110 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 46 | 0.110 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 168 | 0.110 |
Why?
|
| Gastroenterology | 1 | 2015 | 146 | 0.110 |
Why?
|
| Preoperative Care | 2 | 2013 | 395 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2016 | 954 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 1451 | 0.100 |
Why?
|
| Logistic Models | 4 | 2017 | 1214 | 0.100 |
Why?
|
| Global Health | 1 | 2014 | 193 | 0.100 |
Why?
|
| Health Promotion | 1 | 2014 | 165 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 850 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2014 | 234 | 0.100 |
Why?
|
| Debridement | 1 | 2012 | 59 | 0.100 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 51 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2765 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 1729 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 607 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2014 | 1496 | 0.090 |
Why?
|
| Acute Disease | 2 | 2023 | 844 | 0.090 |
Why?
|
| Drainage | 1 | 2012 | 165 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 526 | 0.090 |
Why?
|
| Ethanol | 3 | 2002 | 252 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 2648 | 0.090 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 84 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 377 | 0.090 |
Why?
|
| Hypercapnia | 1 | 2009 | 44 | 0.080 |
Why?
|
| Animals | 7 | 2010 | 27512 | 0.080 |
Why?
|
| Anticoagulants | 3 | 2020 | 428 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 46 | 0.080 |
Why?
|
| Calcium Channel Blockers | 1 | 2009 | 121 | 0.080 |
Why?
|
| Kidney Tubular Necrosis, Acute | 2 | 2021 | 9 | 0.080 |
Why?
|
| Infant | 4 | 2023 | 3187 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 153 | 0.080 |
Why?
|
| Gentamicins | 1 | 2008 | 20 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 364 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2013 | 555 | 0.080 |
Why?
|
| Rhabdomyolysis | 1 | 2008 | 28 | 0.080 |
Why?
|
| Models, Animal | 1 | 2009 | 277 | 0.080 |
Why?
|
| Heart Defects, Congenital | 1 | 2011 | 365 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 2505 | 0.070 |
Why?
|
| North America | 2 | 2013 | 188 | 0.070 |
Why?
|
| Preoperative Period | 2 | 2011 | 94 | 0.070 |
Why?
|
| Elective Surgical Procedures | 1 | 2008 | 128 | 0.070 |
Why?
|
| Canada | 2 | 2020 | 208 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 778 | 0.070 |
Why?
|
| Cause of Death | 2 | 2019 | 269 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2008 | 458 | 0.060 |
Why?
|
| Adolescent | 3 | 2013 | 9327 | 0.060 |
Why?
|
| Datasets as Topic | 1 | 2024 | 75 | 0.060 |
Why?
|
| Mice, Inbred Strains | 2 | 2002 | 308 | 0.060 |
Why?
|
| Chemokines | 1 | 2023 | 74 | 0.050 |
Why?
|
| Microcirculation | 1 | 2023 | 105 | 0.050 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2022 | 6 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 167 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2023 | 165 | 0.050 |
Why?
|
| Causality | 1 | 2022 | 80 | 0.050 |
Why?
|
| Immunoassay | 2 | 2013 | 91 | 0.050 |
Why?
|
| Reagent Strips | 1 | 2011 | 4 | 0.050 |
Why?
|
| Ventilators, Mechanical | 1 | 2022 | 35 | 0.050 |
Why?
|
| Immunosenescence | 1 | 2021 | 4 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2021 | 82 | 0.050 |
Why?
|
| Catalepsy | 1 | 2000 | 3 | 0.050 |
Why?
|
| Hematuria | 1 | 2021 | 50 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 66 | 0.050 |
Why?
|
| Lod Score | 1 | 2000 | 152 | 0.050 |
Why?
|
| Viral Load | 1 | 2021 | 145 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 376 | 0.040 |
Why?
|
| Interferon Type I | 1 | 2021 | 186 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 167 | 0.040 |
Why?
|
| Galectins | 1 | 2019 | 11 | 0.040 |
Why?
|
| APACHE | 1 | 2019 | 22 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2011 | 682 | 0.040 |
Why?
|
| Tertiary Prevention | 1 | 2019 | 2 | 0.040 |
Why?
|
| Arousal | 1 | 2000 | 170 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 156 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2019 | 149 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 12 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2021 | 435 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2019 | 55 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 201 | 0.040 |
Why?
|
| Ventricular Remodeling | 1 | 2019 | 107 | 0.040 |
Why?
|
| Professional Role | 1 | 2019 | 41 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1713 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2019 | 82 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2019 | 158 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2002 | 614 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 244 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2019 | 143 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 158 | 0.040 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 179 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 149 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 433 | 0.040 |
Why?
|
| Research | 1 | 2019 | 251 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 1184 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2498 | 0.040 |
Why?
|
| Mice, Inbred DBA | 3 | 2002 | 150 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2017 | 40 | 0.040 |
Why?
|
| Internationality | 1 | 2017 | 69 | 0.040 |
Why?
|
| Health Personnel | 1 | 2019 | 214 | 0.030 |
Why?
|
| Social Perception | 1 | 2017 | 94 | 0.030 |
Why?
|
| Decision Trees | 1 | 2016 | 59 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 121 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2017 | 222 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 981 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 2015 | 67 | 0.030 |
Why?
|
| Reimbursement Mechanisms | 1 | 2015 | 41 | 0.030 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2015 | 14 | 0.030 |
Why?
|
| Ebolavirus | 1 | 2015 | 7 | 0.030 |
Why?
|
| Patient Isolation | 1 | 2015 | 14 | 0.030 |
Why?
|
| Communication | 1 | 2019 | 461 | 0.030 |
Why?
|
| Body Fluids | 1 | 2015 | 34 | 0.030 |
Why?
|
| Developed Countries | 1 | 2015 | 25 | 0.030 |
Why?
|
| Contraindications | 1 | 2015 | 70 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2025 | 0.030 |
Why?
|
| Equipment Contamination | 1 | 2015 | 25 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 740 | 0.030 |
Why?
|
| Africa | 1 | 2015 | 101 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 293 | 0.030 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2015 | 52 | 0.030 |
Why?
|
| Mice | 4 | 2002 | 11846 | 0.030 |
Why?
|
| Travel | 1 | 2015 | 72 | 0.030 |
Why?
|
| Mortality | 1 | 2015 | 149 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2015 | 156 | 0.030 |
Why?
|
| Receptors, Angiotensin | 1 | 2013 | 12 | 0.030 |
Why?
|
| Acetylcholinesterase | 1 | 2013 | 48 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2015 | 294 | 0.030 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2013 | 45 | 0.030 |
Why?
|
| Enzyme Assays | 1 | 2013 | 16 | 0.030 |
Why?
|
| Health Policy | 1 | 2015 | 188 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 261 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 260 | 0.030 |
Why?
|
| Equipment Design | 1 | 2013 | 421 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1083 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 421 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 302 | 0.020 |
Why?
|
| Medicare | 1 | 2015 | 427 | 0.020 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2011 | 1 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 726 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 1890 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 655 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 871 | 0.020 |
Why?
|
| Organ Dysfunction Scores | 1 | 2010 | 27 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 384 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 654 | 0.020 |
Why?
|
| Mass Screening | 1 | 2015 | 645 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 2360 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2002 | 3250 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2002 | 1091 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2002 | 148 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 476 | 0.010 |
Why?
|
| Haloperidol | 1 | 2000 | 29 | 0.010 |
Why?
|
| Dopamine Antagonists | 1 | 2000 | 34 | 0.010 |
Why?
|
| Central Nervous System Depressants | 1 | 2000 | 45 | 0.010 |
Why?
|
| Genotype | 1 | 2002 | 1853 | 0.010 |
Why?
|
| Phenotype | 1 | 2001 | 2450 | 0.010 |
Why?
|